Method for Diagnosing Diseases Based on Levels of Anti-Glycan Antibodies
AssigneeGlycominds Ltd.
InventorsNir Dotan, Avinoam Dukler
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for diagnosing Crohn's disease (CD) or anti-phospholipid syndrome by measuring levels of antibodies to glycans in a biological sample.
Claims42
A method of diagnosing Crohn's disease in a subject, the method comprising
- providing a test sample from a subject;
- and
- determining whether at least one an anti-glycan antibody is present in said sample, wherein said at least one anti-glycan antibody is selected from the group consisting of an anti-Glc (β) antibody, an anti-Glc (β 1-4) Glc (β) antibody, an anti-Glc (β 1-3) Glc (β) antibody, an anti-GlcNAc 6-sulfate (β) antibody an anti-Dextran antibody, an anti-Xylan antibody, an anti-GlcNAc (β 1-4) GlcNAc (β) antibody, an anti-Gal 3 sulphate (β) antibody, an anti-GlcNAc (β 1-3) GalNAc (β) antibody, an anti-GlcNAc (β 1-3) Gal (β 1-4) Glc (β) antibody, and an anti-Gal (α 1-3) Gal (β 1-4) GlcNAc (β) antibody;
- wherein the presence of said antibody in said test sample indicates the subject has Crohn's disease.
A method of diagnosing Crohn's disease in a subject, the method comprising
- providing a test sample from a subject;
- and
- determining whether an anti-glycan antibody is present in said test sample, wherein said at least one anti-glycan antibody is selected from the group consisting of an IgG Glc (β 1-3) Glc (β) antibody and an IgG anti-Man (α 1-3) Man (α) antibody,
- wherein the presence of said at least one antibody in said test sample indicates the subject has Crohn's disease.
A method of differentially diagnosing Crohn's disease or inflammatory bowel disease in a subject, the method comprising
- providing a test sample from a subject;
- and
- determining whether said antibodies are present in said sample, said antibodies comprising
- anti-neutrophil cytoplasmic antibody (ANCA),
- IgG anti-Glc (β 1-3) Glc (β)
- IgG ASCA;
- and
- IgA ASCA,
- wherein the absence of ANCA and the presence of at least one of said IgG anti-Glc (β 1-3) Glc (β) IgG ASCA, and IgA ASCA antibodies in said test sample indicates the subject has Crohn's disease, and
- wherein the presence of at least one of said antibodies in said test sample indicates the subject has inflammatory bowel disease (UC or CD).
A kit for diagnosing Crohn's Disease, the kit comprising one or more reagents that specifically detect an antibody selected from the group consisting of an anti-Glc (β) antibody, an anti-Glc (β 1-4) Glc (β) antibody, an anti-Glc (β 1-3) Glc (β) antibody, an anti-GlcNAc 6-sulfate (β) antibody, an anti-Man (α 1-2) Man (α) antibody, an anti-Man (α 1-3) Man (α) antibody, an anti-Man (α 1-6) Man (α) antibody, an anti-Man (α) antibody, an anti-Man (α 1-3)[Man (α 1-6)] Man (α), an anti-Dextran antibody, an anti-Xylan antibody, an anti-GlcNAc (β 1-4) GlcNAc (β) antibody, an anti-Gal 3 sulphate (β) antibody, an anti-aGlcNAc (β 1-3) GalNAc (β) antibody, an anti-GlcNAc (β 1-3) Gal (β 1-4) Glc (β) antibody, and an anti-Gal (α 1-3) Gal (β 1-4) GlcNAc (β) antibody.
An array comprising a plurality of carbohydrate reagents that specifically detect an antibody selected from the group consisting of an anti-Glc (β) antibody, an anti-Glc (β1-4) Glc (β) antibody, an anti-Glc (β 1-3) Glc (β) antibody, an anti-GlcNAc 6-sulfate (β) antibody, an anti-Man (α 1-2) Man (α) antibody, an anti-Man (α 1-3) Man (α) antibody, an anti-Man (α 1-6) Man (α) antibody, an anti-Man (α) antibody, an anti-Man (α 1-3)[Man (α 1-6)] Man (α), an anti-Dextran antibody, an anti-Xylan antibody, an anti-GlcNAc (β 1-4) GlcNAc (β) antibody, an anti-Gal 3 sulphate (β) antibody, an anti-aGlcNAc (β 1-3) GalNAc (β) antibody, an anti-GlcNAc (β 3-3) Gal (β 1-4) Glc (β) antibody, and an anti-Gal (α 1-3) Gal (β 1-4) GlcNAc (β) antibody, wherein said reagents are attached at an addressable location on said array.
Dependencies are inferred from the claim text.